ArticleScientific reports2026
Biotransformation of obefazimod, a novel potential anthelmintic, in sheep and the target nematode Haemonchus contortus.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Parasitic nematodes cause significant health issues in livestock, resulting in clinical complications and economic losses worldwide. As the efficacy of current anthelmintic drugs is being compromised by the emergence of drug resistance, a search for novel therapeutics with new modes of action is necessary. Obefazimod (ABX464) originally developed for human inflammatory diseases, has recently shown promising nematocidal activity against Haemonchus contortus and other parasitic nematodes. This study aimed to elucidate the biotransformation pathways of obefazimod in H. contortus and in its host, sheep. Adult nematodes (females and males separately) of drug-susceptible and drug-resistant strains and ovine liver models were used. Using a newly developed and optimized UHPLC-HRMS/MS method, we identified 13 metabolites formed via phase I and II metabolism. These findings provide the first insight into the metabolic fate of obefazimod in target parasites and host species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.